Skip to content

AstraZeneca’s Imfinzi OK’d in Europe for first-line lung cancer

September 1, 2020

AstraZeneca’s (NYSE:AZN) Imfinzi (durvalumab) has been approved in the European Union for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin.

The approval was based on positive results from the Phase III CASPIAN trial of Imfinzi plus chemotherapy in ES-SCLC.

It also follows the recommendation for approval by the EMA’s advisory group CHMP in July 2020

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: